SPR1NT (NCT03505099) is an ongoing multicenter, open-label, phase 3, single arm, trial aimed to evaluate the safety and efficacy of a onasemnogene abeparvovec in presymptomatic SMA patients under 6 weeks of age who have two to three copies of SMN2 gene. The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.